Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.9013 USD
−121.83 M USD
0.00 USD
22.37 M
About Prelude Therapeutics Incorporated
Sector
Industry
CEO
Krishna Vaddi
Website
Headquarters
Wilmington
Founded
2016
FIGI
BBG00K7JY2Q6
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where PRLD is featured.
Frequently Asked Questions
The current price of PRLD is 0.9487 USD — it has decreased by −1.91% in the past 24 hours. Watch Prelude Therapeutics Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Prelude Therapeutics Incorporated stocks are traded under the ticker PRLD.
PRLD stock has fallen by −9.65% compared to the previous week, the month change is a −45.16% fall, over the last year Prelude Therapeutics Incorporated has showed a −70.81% decrease.
We've gathered analysts' opinions on Prelude Therapeutics Incorporated future price: according to them, PRLD price has a max estimate of 7.00 USD and a min estimate of 1.00 USD. Watch PRLD chart and read a more detailed Prelude Therapeutics Incorporated stock forecast: see what analysts think of Prelude Therapeutics Incorporated and suggest that you do with its stocks.
PRLD reached its all-time high on Feb 10, 2021 with the price of 95.3750 USD, and its all-time low was 0.9310 USD and was reached on Nov 18, 2024. View more price dynamics on PRLD chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PRLD stock is 3.30% volatile and has beta coefficient of 0.15. Track Prelude Therapeutics Incorporated stock price on the chart and check out the list of the most volatile stocks — is Prelude Therapeutics Incorporated there?
Today Prelude Therapeutics Incorporated has the market capitalization of 52.21 M, it has decreased by −7.00% over the last week.
Yes, you can track Prelude Therapeutics Incorporated financials in yearly and quarterly reports right on TradingView.
Prelude Therapeutics Incorporated is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
PRLD earnings for the last quarter are −0.43 USD per share, whereas the estimation was −0.47 USD resulting in a 8.90% surprise. The estimated earnings for the next quarter are −0.47 USD per share. See more details about Prelude Therapeutics Incorporated earnings.
Prelude Therapeutics Incorporated revenue for the last quarter amounts to 3.00 M USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
PRLD net income for the last quarter is −32.27 M USD, while the quarter before that showed −34.74 M USD of net income which accounts for 7.11% change. Track more Prelude Therapeutics Incorporated financial stats to get the full picture.
No, PRLD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has 128.00 employees. See our rating of the largest employees — is Prelude Therapeutics Incorporated on this list?
Like other stocks, PRLD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Prelude Therapeutics Incorporated stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Prelude Therapeutics Incorporated technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Prelude Therapeutics Incorporated stock shows the sell signal. See more of Prelude Therapeutics Incorporated technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.